NCT01724177已完成2 期
A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Celgene
- 入组人数
- 26
- 试验地点
- 18
- 主要终点
- Percentage of Participants Who Achieved a Complete Response, Unconfirmed Complete Response, or Partial Response as Assessed by the Efficacy-Safety Evaluation Committee (ESEC)
研究概览
简要总结
To evaluate the efficacy of lenalidomide in patients with Adult T-cell Leukemia-lymphoma (ATL) who have previously received chemotherapy for ATL.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must understand and voluntarily sign the informed consent
- •Aged 20 years or older (at the time of signing the informed consent)
- •Have a documented diagnosis of either: acute-, lymphoma-, or unfavorable chronic-type adult T-cell leukemia-lymphoma
- •Have received ≥1 prior anti-adult T-cell leukemia-lymphoma therapy, have achieved stable disease or better on their immediately prior therapy and have relapsed or progressed at the time of obtaining signed informed consent
- •Subjects for whom at least 1 measurable lesion (measurable lesion of computed tomography scan, peripheral blood or skin lesion) is confirmed in the lesion assessment before registration
- •Have an Eastern Cooperative Oncology Group performance status of 0 to 2 at registration
- •Must be able to adhere to the study visit schedule and other protocol requirements
- •Must agree to comply to Lenalidomide Pregnancy Prevention Risk Management Plan
排除标准
- •Have a history of central nervous system involvement or present with central nervous system symptoms, and are diagnosed with central nervous system lymphoma by cerebrospinal fluid cytology examination, head computed tomography scan or brain magnetic resonance imaging during the screening
- •Are pregnant or lactating
- •Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study. Examples of such medical condition are, but are not limited to, as follows:
- •Uncontrolled diabetes mellitus as defined by the investigator or sub-investigator
- •Chronic congestive heart failure (New York Heart Association Class III or IV)
- •Unstable angina pectoris, angioplasty, stenting, or myocardial infarction (within 6 months before starting the study drug)
- •Clinically significant cardiac arrhythmia that is symptomatic or requires treatment, or asymptomatic sustained ventricular tachycardia (subjects with controlled atrial fibrillation that is asymptomatic are eligible for this study)
- •Major surgery within 28 days of the start of study treatment
- •Exhibit grade 4 neurological disorders
- •Patients who are at a high risk for a thromboembolic event and are not willing to take venous thromboembolic prophylaxis.
- •Develop active tuberculous disease, herpes simplex, systemic mycosis, or other active infections requiring systemic administration of antibiotics, antiviral agents, or antifungal drugs
- •Known human immunodeficiency virus positivity
- •Have hepatitis B surface antigen-positive, or hepatitis C virus anti-body positive. In case hepatitis B core antibody and/or hepatitis B surface antibody is positive even if hepatitis B surface antigen-negative, a hepatitis B virus deoxyribonucleic acid test should be performed and if positive the subject will be excluded
- •Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
- •Have a history of allogenic stem cell transplantation
- •Have received autologous stem cell transplantation within 12 weeks (84 days) of the start of study treatment
- •Have previously used lenalidomide
- •Have a history of desquamating (blistering) rash while taking thalidomide
- •Have received any investigational drugs (unapproved drugs in Japan) within 4 weeks (28 days) of the start of study medication
- •Have received any antibody agents within 12 weeks (84 days) of the start of study medication
- •Have received chemotherapeutic agents or immunomodulatory drugs for the treatment of adult T-cell leukemia-lymphoma within 4 weeks (28 days) of the start of study treatment
- •Have received radiotherapy within 4 weeks (28 days) of the start of study treatment
- •Have a history or complication of another malignant tumor other than adult T-cell leukemia-lymphoma and the following malignant tumors, unless the patients have been free of the disease for 5 years or longer
- •Basal cell carcinoma of the skin
- •Squamous cell carcinoma of the skin
- •Cervical carcinoma in situ
- •Carcinoma in situ of the breast
- •An incidental histological finding of prostate carcinoma (TNM stage T1a or T1b)
- •Early-stage gastric cancer treated with endoscopic mucosal resection or endoscopic submucosal dissection
- •Have had any of the following abnormal measurements at screening performed within 1 week (7 days) prior to the registration;
- •Neutrophil count: < 1,200/µL
- •Platelet count: < 75,000/µL
- •Serum aspartate aminotransferase/glutamyl oxaloacetic transaminase or alanine aminotransferase/glutamyl pyruvic transaminase: > 3 times the upper limit of normal
- •Bilirubin level: > 1.5 times the upper limit of normal
- •Creatinine clearance: < 60 mL/min
- •Any condition that confounds the ability to interpret data from the study.
研究组 & 干预措施
Lenalidomide
Experimental
Lenalidomide 25mg by mouth (PO) daily until progressive disease or unacceptable toxicity
干预措施: Lenalidomide (Drug)
结局指标
主要结局
Percentage of Participants Who Achieved a Complete Response, Unconfirmed Complete Response, or Partial Response as Assessed by the Efficacy-Safety Evaluation Committee (ESEC)
时间窗: From day 1 of study treatment to date of first documented CR, CRU or PR; Up to data cut-off date of 19 May 2017; maximum study duration was 134.1 weeks
ORR is a Complete Response (CR) + Complete Response unconfirmed (CRu) + Partial Response (PR). A CR requires that target lesions have regressed to normal; nodal non-target lesions have regressed to normal; extranodal non-target lesions have disappeared; hepatomegaly/splenomegaly has disappeared; skin findings are GR 0; peripheral blood is normal; Bone marrow (BM) infiltration is negative and no new lesions. A CRu requires the sum of the product diameters (SPD) of target lesions have decreased by at least 75% from baseline; nodal non-target lesions have regressed to normal size; extranodal non-target lesions have disappeared; hepatomegaly/splenomegaly has disappeared; skin findings are Grade 0; peripheral blood is normal; BM infiltration is "negative" and no new lesions. A PR requires the SPD of target lesions has decreased by at least 50% from baseline; all nodal non-target lesions have regressed to normal or show no increase in size; all extranodal non-target lesions have disappeared
次要结局
- Kaplan-Meier Estimate of Time to Progression (TTP)(From day 1 of study treatment to the date of disease progression; up to data cut date of 19 May 2017; maximum study duration was 134.1 weeks)
- Kaplan Meier Estimate of Progression Free Survival (PFS) as Assessed by the ESEC(From day 1 of study treatment to the date of disease progression; up to data cut date of date of 19 May 2017; maximum study duration was 134.1 weeks)
- Number of Participants With Treatment Emergent Adverse Events(From the date of the first dose of study drug up to 28 days after the last dose of study drug; up to data cutoff date of 19 May 2017; maximum treatment duration was 130.1 weeks)
- Percentage of Participants Who Achieved a Complete Response, Unconfirmed Complete Response (CRu), Partial Response or Stable Disease (SD) as Assessed by the ESEC(From day 1 of study treatment to first documented response; up to data cut-off date of 19 May 2017; maximum study duration was 134.1 weeks)
- Kaplan-Meier Estimate for Overall Survival(From Day 1 of study treatment to disease progression or death; up to final data cut-off date of 19 May 2017; maximum surivival time was 197.9 weeks)
- Kaplan-Meier Estimate of Duration of Response (DOR) for Responders as Assessed by the ESEC(From day 1 of study treatment to first documented response; up to data cut-off date of 19 May 2017; Maximum study duration was 134.1 Weeks)
研究者
研究点 (18)
Loading locations...
相似试验
已完成
2 期
Lenalidomide in HTLV-1 Adult T-Cell LeukemiaAdult T Cell Leukemia/LymphomaNCT01274533Columbia University4
已完成
1 期
A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell LymphomaAdult T-cell Leukemia-LymphomaPeripheral T-cell LymphomaNCT01169298Celgene13
撤回
2 期
Lenalidomide and Obinutuzumab for Previously Untreated CLLChronic Lymphocytic LeukemiaNCT02371590University of California, San Diego
已完成
2 期
Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's LymphomaHodgkin DiseaseNCT00478959University Health Network, Toronto30
Unknown
2 期
Lenalidomide and Low-dose Cyclophosphamide for MALT LymphomaAntibiotics-unresponsive MALT LymphomaRelapsed MALT Type Extranodal Marginal Zone B-Cell LymphomaRefractory Extranodal Marginal Zone B-Cell Lymphoma (MALT)NCT04604028National Taiwan University Hospital21